Skip to content

Rafael Holdings, Inc. RFL US — Total Assets

Other geography segments

IL
$2.5M-33.1%

Similar metrics at other companies

RDI
RDIUS — Total Assets
$240.17M-5.9%
BioSig Technologies, Inc. logo
STEXUS — Total Assets
$56.39M
International Tower Hill Mines logo
THMUS — Total Assets
$55.83M0.0%
FTE
FTEKUS — Total Assets
$41.75M-2.4%
Profound Medical logo
PROFUS — Total Assets
$7.39M+18.0%
Climb Global Solutions, Inc. logo
CLMBUS — Total Assets
$281.66M+27.2%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s us — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s US — total assets?
Rafael Holdings, Inc. (RFL) reported US — total assets of $89.53M in Q1 2026.
How has Rafael Holdings, Inc.'s US — total assets changed year-over-year?
Rafael Holdings, Inc.'s US — total assets decreased by 15.5% year-over-year, from $105.97M to $89.53M.
What does US — total assets mean?
Reflects the total economic resources controlled by the company within its US operations, encompassing both current and non-current assets. This figure provides a comprehensive view of the capital deployed in the US market to support the company's oncology-focused pharmaceutical development and investment activities.